SequelSEC

CV Sciences, Inc. CVSI

Pharmaceutical Preparations · CIK 0001510964 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$2.98M
Fiscal year ended 2026-06-30
Operating income
-$301.00K
Fiscal year ended 2026-06-30
Free cash flow
$13.00K
Fiscal year ended 2026-06-30

CV Sciences, Inc. (CVSI) reported revenue of $2.98M and net income of -$775.00K for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from CV Sciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

CV Sciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$2.98M$3.20M$3.31M$3.26M$3.62M$3.61M$3.88M$3.86M$3.95M$4.00M
Cost of revenue$1.54M$1.63M$1.64M$1.68M$1.78M$1.95M$2.21M$2.09M$2.09M$2.15M
Gross profit$1.45M$1.56M$1.67M$1.58M$1.84M$1.66M$1.68M$1.78M$1.86M$1.85M
Operating income-$301.00K-$318.00K-$75.00K-$275.00K-$131.00K$11.00K-$646.00K-$341.00K-$583.00K-$620.00K
Net income-$775.00K-$643.00K-$206.00K-$382.00K-$261.00K-$109.00K-$726.00K-$456.00K-$584.00K-$628.00K
Research & development$18.00K$18.00K$18.00K$24.00K$50.00K$30.00K$25.00K$29.00K$28.00K$36.00K
Weighted-average diluted sharesshares 205.09Mshares 186.92MUnavailableshares 184.26Mshares 184.26Mshares 184.26MUnavailableshares 182.26Mshares 172.42Mshares 163.08M
Pretax income-$770.00K-$643.00K-$204.00K-$382.00K-$261.00K-$102.00K-$740.00K-$456.00K-$584.00K-$622.00K
Income tax expense$5.00K$0$2.00K$0$0$7.00K-$14.00K$0$0$6.00K
Diluted EPS$0.00$0.00Unavailable$0.00$0.00$0.00Unavailable$0.00$0.00$0.00
Selling, general & administrative$1.73M$1.86M$1.73M$1.83M$1.92M$2.14M$2.30M$2.09M$2.42M$2.44M
General & administrative$708.00K$788.00K$647.00K$710.00K$836.00K$960.00K$996.00K$740.00K$1.25M$1.00M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

CV Sciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total assets$6.52M$6.72M$6.96M$7.00M$7.95M$7.76M$7.93M$8.39M$8.89M$8.47M
Current assets$4.88M$5.00M$5.13M$5.10M$5.94M$5.96M$6.24M$6.75M$6.73M$7.35M
Total liabilities$4.95M$5.22M$5.49M$5.46M$6.15M$5.87M$6.13M$6.20M$6.38M$6.10M
Current liabilities$4.94M$5.18M$5.00M$4.79M$5.70M$5.25M$6.11M$6.14M$6.03M$5.96M
Total equity incl. NCI$1.57M$1.50M$1.47M$1.54M$1.80M$1.89M$1.80M$2.19M$2.51M$2.36M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$3.96M$3.90M$4.09M$4.08M$4.22M$4.37M$4.90M$5.02M$5.21M$5.76M
Accounts receivable$348.00K$391.00K$402.00K$405.00K$545.00K$430.00K$522.00K$422.00K$639.00K$507.00K
Goodwill$999.00K$1.00M$1.02M$1.01M$1.01M$988.00K$971.00K$815.00K$729.00K$340.00K
Long-term debt$0$0$387.00K$504.00K$208.00K$498.00K$0UnavailableUnavailableUnavailable
Accounts payable$1.06M$1.08M$1.04M$1.21M$1.44M$1.50M$1.92M$1.89M$2.31M$2.46M

Cash flow

CV Sciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$20.00K$101.00K-$354.00K-$259.00K$287.00K-$81.00K-$164.00K-$122.00K-$57.00K-$518.00K
Capital expenditures$7.00K$3.00K$9.00K$11.00K$49.00K$40.00K$18.00K$0$0$0
Investing cash flow-$7.00K-$3.00K-$9.00K-$11.00K-$49.00K-$40.00K-$22.00K$34.00K-$40.00K$0
Financing cash flow-$54.00K-$68.00K$258.00K-$234.00K-$167.00K$480.00K-$335.00K$590.00K-$87.00K-$136.00K
Net change in cash-$43.00K$31.00K-$103.00K-$505.00K$74.00K$358.00K-$525.00K$502.00K-$185.00K-$655.00K
Stock-based compensation$148.00K$148.00K$123.00K$124.00K$132.00K$118.00K$104.00K$87.00K$37.00K$30.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$22.00K$23.00K$21.00K$31.00K$58.00K$82.00K$114.00K$81.00K$76.00K$63.00K

Derived

CV Sciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow$13.00K$98.00K-$363.00K-$270.00K$238.00K-$121.00K-$182.00K-$122.00K-$57.00K-$518.00K
Gross margin48.6%48.9%50.5%48.5%50.9%46.0%43.2%46.0%47.0%46.3%
Operating margin-10.1%-10.0%-2.3%-8.4%-3.6%0.3%-16.6%-8.8%-14.7%-15.5%
FCF margin0.4%3.1%-11.0%-8.3%6.6%-3.4%-4.7%-3.2%-1.4%-12.9%
SBC / revenue5.0%4.6%3.7%3.8%3.6%3.3%2.7%2.3%0.9%0.7%
Current ratio0.99x0.96x1.03x1.06x1.04x1.14x1.02x1.10x1.12x1.23x
Revenue YoY growth-17.5%-11.4%-14.9%-15.8%-8.4%-9.9%2.2%-5.5%-0.3%-3.5%
Net margin-26.0%Unavailable-6.2%-11.7%-7.2%Unavailable-18.7%-11.8%UnavailableUnavailable
R&D / revenue0.6%0.6%0.5%0.7%1.4%0.8%0.6%0.8%0.7%0.9%
CapEx / revenue0.2%0.1%0.3%0.3%1.4%1.1%0.5%0.0%0.0%0.0%
Long-term debt / equity0.00xUnavailable0.26x0.33xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CVSI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.